echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Kelun Class 1 new drug hits 2 billion injections, the first four major products that have been reviewed and will be approved

    Kelun Class 1 new drug hits 2 billion injections, the first four major products that have been reviewed and will be approved

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Kelun Pharmaceutical has good news again and again.


    On April 7, the clinical application of KL590586 capsule, a new class 1 drug of Sichuan Kelun Botai, a subsidiary of Kelun Pharmaceutical, was accepted by CDE, with the acceptance numbers CXHL2101023 and CXHL2101024.


    On April 8, the official website of NMPA showed that Kelun Pharmaceutical's alanyl glutamine injection passed the consistency evaluation.


    In terms of generic drugs, Kelun Pharmaceutical has ushered in a harvest period.


    Kelun Pharmaceutical is approving varieties

    Source: Meinenet MED2.


    Moxifloxacin hydrochloride eye drops is a fourth-generation quinolone broad-spectrum antibacterial drug.


    Ropivacaine Hydrochloride Injection is a new long-acting amide local anesthetic developed by AstraZeneca, and it is the leading drug in the local anesthetic market.


    According to data from Minai.


    Source: Minet database

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.